Angiotensin II-dependent Src and Smad1 signaling pathway is crucial for the development of diabetic nephropathy

Laboratory Investigation

Volumn 86, Issue 9, 2006, Pages 927-939

  Mima, Akira ^a   Matsubara, Takeshi ^a   Arai, Hidenori ^a   Abe, Hideharu ^b   Nagai, Kojiro ^a   Kanamori, Hiroshi ^a   Sumi, Eriko ^a   Takahashi, Toshikazu ^b   Iehara, Noriyuki ^a   Fukatsu, Atsushi ^a   Kita, Toru ^a   Doi, Toshio ^b  

^a KYOTO UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Angiotensin II; Diabetic nephropathy; Mesangial matrix expansion; Smad1; Src; Type IV collagen

Indexed keywords

4 AMINO 7 TERT BUTYL 5 (4 CHLOROPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; ALPHA SMOOTH MUSCLE ACTIN; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSIN II; COLLAGEN TYPE 4; OLMESARTAN; PHOSPHO SMAD1 PROTEIN; PHOSPHO SRC PROTEIN; PROTEIN; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; SMAD1 PROTEIN; SMALL INTERFERING RNA; STREPTOZOCIN; UNCLASSIFIED DRUG;

ALBUMINURIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MALE; MESANGIUM CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; RAT; ULTRAFILTRATION; WESTERN BLOTTING;

ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; BUTADIENES; CELL LINE; COLLAGEN TYPE IV; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; GENE EXPRESSION; GLOMERULAR MESANGIUM; IMIDAZOLES; MALE; MESANGIAL CELLS; NITRILES; PHOSPHORYLATION; PYRIMIDINES; RATS; RATS, SPRAGUE-DAWLEY; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SMAD1 PROTEIN; SRC-FAMILY KINASES; TETRAZOLES;

EID: 33747594262     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.3700445     Document Type: Article

References (55)

1. Striker GE, Schainuck LI, Cutler RE, et al. Structural-functional correlations in renal disease. I. A method for assaying and classifying histopathologic changes in renal disease. Hum Pathol 1970;1:615-630.
2. Alpers CE, Hudkins KL, Gown AM, et al. Enhanced expression of 'muscle-specific' actin in glomerulonephritis. Kidney Int 1992;41:1134-1142.
3. Ziyadeh FN. The extracellular matrix in diabetic nephropathy. Am J Kidney Dis 1993;22:736-744.
4. Fogo AB. Diabetic nephropathy: it's in the numbers. Kidney Int 2002;61:2274-2275.
5. Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993;329:1456-1462.
6. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-869.
7. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-860.
8. Ruggenenti P, Perna A, Gherardi G, et al. Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy. Lancet 1998;352:1252-1256.
9. Mimran A, Alfaro V. Candesartan: nephroprotective effects and treatment of diabetic nephropathy. Drugs Today (Barc) 2003;39:439-450.
10. Anderson S, Jung FF, Ingelfinger JR. Renal renin-angiotensin system in diabetes: functional, immunohistochemical, and molecular biological correlations. Am J Physiol 1993;265:F477-F486.
11. Anderson S. Role of local and systemic angiotensin in diabetic renal disease. Kidney Int Suppl 1997;63:S107-S110.
12. Ichikawa I, Brenner BM. Glomerular actions of angiotensin II. Am J Med 1984;76:43-49.
13. Anderson S, Rennke HG, Brenner BM. Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest 1986;77:1993-2000.
14. Fogo AB. The role of angiotensin II and plasminogen activator inhibitor-1 in progressive glomerulosclerosis. Am J Kidney Dis 2000;35:179-188.
15. Striker LJ, Doi T, Elliot S, et al. The contribution of glomerular mesangial cells to progressive glomerulosclerosis. Semin Nephrol 1989;9:318-328.
16. Striker LJ, Peten EP, Elliot SJ, et al. Mesangial cell turnover: effect of heparin and peptide growth factors. Lab Invest 1991;64:446-456.
17. Stokes MB, Hudkins KL, Zaharia V, et al. Up-regulation of extracellular matrix proteoglycans and collagen type I in human crescentic glomerulonephritis. Kidney Int 2001;59:532-542.
18. Abe H, Matsubara T, Iehara N, et al. Type IV collagen is transcriptionally regulated by Smad1 under advanced glycation end product (AGE) stimulation. J Biol Chem 2004;279:14201-14206.
19. Matsubara T, Abe H, Arai H, et al. Expression of Smad1 is directly associated with mesangial matrix expansion in rat diabetic nephropathy. Lab Invest 2006;86:357-368.
20. Brown MT, Cooper JA. Regulation, substrates and functions of src. Biochim Biophys Acta 1996;1287:121-149.
21. Fessart D, Simaan M, Laporte SA. c-Src regulates clathrin adapter protein 2 interaction with beta-arrestin and the angiotensin II type 1 receptor during clathrin-mediated internalization. Mol Endocrinol 2005;19:491-503.
22. Waters CM, Connell MC, Pyne S, et al. c-Src is involved in regulating signal transmission from PDGFbeta receptor-GPCR(s) complexes in mammalian cells. Cell Signal 2005;17:263-277.
23. Kansra S, Stoll SW, Johnson JL, et al. Src family kinase inhibitors block amphiregulin-mediated autocrine ErbB signaling in normal human keratinocytes. Mol Pharmacol 2005;67:1145-1157.
24. Liu J, Huang C, Zhan X. Src is required for cell migration and shape changes induced by fibroblast growth factor 1. Oncogene 1999;18:6700-6706.
25. Taneda S, Hudkins KL, Topouzis S, et al. Obstructive uropathy in mice and humans: potential role for PDGF-D in the progression of tubulointerstitial injury. J Am Soc Nephrol 2003;14:2544-2555.
26. Hudkins KL, Gilbertson DG, Carling M, et al. Exogenous PDGF-D is a potent mesangial cell mitogen and causes a severe mesangial proliferative glomerulopathy. J Am Soc Nephrol 2004;15:286-298.
27. Takahashi T, Abe H, Arai H, et al. Activation of STAT3/Smad1 is a key signaling pathway for progression to glomerulosclerosis in experimental glomerulonephritis. J Biol Chem 2005;280:7100-7106.
28. Flyvbjerg A, Bennett WF, Rasch R, et al. Inhibitory effect of a growth hormone receptor antagonist (G120K-PEG) on renal enlargement, glomerular hypertrophy, and urinary albumin excretion in experimental diabetes in mice. Diabetes 1999;48:377-382.
29. Nangaku M, Miyata T, Sada T, et al. Anti-hypertensive agents inhibit in vivo the formation of advanced glycation end products and improve renal damage in a type 2 diabetic nephropathy rat model. J Am Soc Nephrol 2003;14:1212-1222.
30. Makibayashi K, Tatematsu M, Hirata M, et al. A vitamin D analog ameliorates glomerular injury on rat glomerulonephritis. Am J Pathol 2001;158:1733-1741.
31. Yamamoto Y, Kato I, Doi T, et al. Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice. J Clin Invest 2001;108:261-268.
32. Nagai K, Matsubara T, Mima A, et al. Gas6 induces Akt/mTOR-mediated mesangial hypertrophy in diabetic nephropathy. Kidney Int 2005;68:552-561.
33. Pippin JW, Qu Q, Meijer L, et al. Direct in vivo inhibition of the nuclear cell cycle cascade in experimental mesangial proliferative glomerulonephritis with Roscovitine, a novel cyclin-dependent kinase antagonist. J Clin Invest 1997;100:2512-2520.
34. Takeoka H, Iehara N, Uematsu-Yanagita M, et al. A multifunctional transcription factor (A1p145) regulates the smooth muscle phenotype in mesangial cells. Biochem Biophys Res Commun 1998;252:290-295.
35. Nagai K, Arai H, Yanagita M, et al. Growth arrest-specific gene 6 is involved in glomerular hypertrophy in the early stage of diabetic nephropathy. J Biol Chem 2003;278:18229-18234.
36. Stockelman MG, Lorenz JN, Smith FN, et al. Chronic renal failure in a mouse model of human adenine phosphoribosyltransferase deficiency. Am J Physiol 1998;275:F154-F163.
37. Abe H, Iehara N, Utsunomiya K, et al. A vitamin D analog regulates mesangial cell smooth muscle phenotypes in a transforming growth factor-beta type II receptor-mediated manner. J Biol Chem 1999;274:20874-20878.
38. Fogo AB. Mechanisms in nephrosclerosis and hypertension-beyond hemodynamics. J Nephrol 2001;14(Suppl 4):S63-S69.
39. Border WA, Noble NA. Interactions of transforming growth factor-beta and angiotensin II in renal fibrosis. Hypertension 1998;31:181-188.
40. Weigert C, Brodbeck K, Klopfer K, et al. Angiotensin II induces human TGF-beta 1 promoter activation: similarity to hyperglycaemia. Diabetologia 2002;45:890-898.
41. Yang CW, Striker GE, Chen WY, et al. Differential expression of glomerular extracellular matrix and growth factor mRNA in rapid and slowly progressive glomerulosclerosis: studies in mice transgenic for native or mutated growth hormone. Lab Invest 1997;76:467-476.
42. Zatz R, Meyer TW, Rennke HG, et al. Predominance of hemodynamic rather than metabolic factors in the pathogenesis of diabetic glomerulopathy. Proc Natl Acad Sci USA 1985;82:5963-5967.
43. Hanke JH, Gardner JP, Dow RL, et al. Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. Study of Lck- and FynT-dependent T cell activation. J Biol Chem 1996;271:695-701.
44. Liao J, Kobayashi M, Kanamuru Y, et al. Effects of candesartan, an angiotensin II type 1 receptor blocker, on diabetic nephropathy in KK/Ta mice. J Nephrol 2003;16:841-849.
45. Riser BL, Cortes P, Zhao X, et al. Intraglomerular pressure and mesangial stretching stimulate extracellular matrix formation in the rat. J Clin Invest 1992;90:1932-1943.
46. Riser BL, Cortes P, Heilig C, et al. Cyclic stretching force selectively up-regulates transforming growth factor-beta isoforms in cultured rat mesangial cells. Am J Pathol 1996;148:1915-1923.
47. Throckmorton DC, Brogden AP, Min B, et al. PDGF and TGF-beta mediate collagen production by mesangial cells exposed to advanced glycosylation end products. Kidney Int 1995;48:111-117.
48. Fukami K, Ueda S, Yamagishi S, et al. AGEs activate mesangial TGF-beta-Smad signaling via an angiotensin II type I receptor interaction. Kidney Int 2004;66:2137-2147.
49. Nagai Y, Yao L, Kobori H, et al. Temporary angiotensin II blockade at the prediabetic stage attenuates the development of renal injury in type 2 diabetic rats. J Am Soc Nephrol 2005;16:703-711.
50. Singh R, Alavi N, Singh AK, et al. Role of angiotensin II in glucose-induced inhibition of mesangial matrix degradation. Diabetes 1999;48:2066-2073.
51. Border WA. Transforming growth factor-beta and the pathogenesis of glomerular diseases. Curr Opin Nephrol Hypertens 1994;3:54-58.
52. Isaka Y, Brees DK, Ikegaya K, et al. Gene therapy by skeletal muscle expression of decorin prevents fibrotic disease in rat kidney. Nat Med 1996;2:418-423.
53. Ziyadeh FN, Hoffman BB, Han DC, et al. Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal anti-transforming growth factor-beta antibody in db/db diabetic mice. Proc Natl Acad Sci USA 2000;97:8015-8020.
54. Chen S, Iglesias-de la Cruz MC, Jim B, et al. Reversibility of established diabetic glomerulopathy by anti-TGF-beta antibodies in db/db mice. Biochem Biophys Res Commun 2003;300:16-22.
55. Sabri A, Govindarajan G, Griffin TM, et al. Calcium- and protein kinase C-dependent activation of the tyrosine kinase PYK2 by angiotensin II in vascular smooth muscle. Circ Res 1998;83:841-851.